AZD6234 for adults with obesity or overweight and no type 2 diabetes
Tests AZD6234 against placebo in adults with obesity or overweight.
Key facts
- Who runs it
- AstraZeneca
- Where
- Anyang, Bucheon-si, Daegu, Seoul, and Yangsan, South KoreaSee the 5 sitesAlso in 15 other countries, 211 sites
- Trial code
- Registry title
- A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 2,500 people, planned
- Started
- 19 Aug 2026
- Expected to end
- 21 May 2029
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Lenbelintide
- Placebo
- Record updated
- 30 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity, or with overweight and at least one weight-related health problem, who do not have diabetes. AZD6234 is compared with placebo over 68 weeks.
- Age
- 18 years or older
- Sex
- All sexes and genders can join.
- Disease stage
- BMI 30 kg/m2 or higher, or BMI 27 kg/m2 or higher with at least one weight-related health problem such as high blood pressure, high blood fats, sleep apnoea, heart disease, heart failure, chronic kidney disease, fatty liver disease, knee osteoarthritis or stress urinary incontinence.
- Earlier treatment
- Must have had at least one unsuccessful attempt to lose weight in their lifetime. Must not have had a GLP-1 receptor agonist or GLP-1 containing medicine within 3 months before randomisation.
Main reasons for not taking part
- Obesity mainly caused by other hormone disorders
- Type 1 or Type 2 diabetes, HbA1c 6.5% (48 mmol/mol) or higher, or glucose-lowering medicine in the 3 months before screening
- Significant liver or bile duct disease, or ALT or AST 3.0 × ULN or higher, or TBL above 1.5 × ULN at screening
- Body weight change of more than 5% in the 3 months before randomisation
- GLP-1 medicine within 3 months before randomisation
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Males \& females (inclusive of all gender identities) age ≥18 years
- BMI ≥30 kg/m2 OR BMI ≥27 kg/m2 with at least one of the following weight related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, heart failure, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, osteoarthritis of the knee, or stress urinary incontinence
- Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation
- History of at least one self-reported unsuccessful attempt to lose body weight in their lifetime
Who cannot take part
- Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation
- Obesity primarily caused by other endocrine disorders
- History of Type 1 or Type 2 Diabetes Mellitus, HbA1c ≥6.5% (48 mmol/mol), and/or treatment with glucose-lowering agent(s) within 3 months prior to Screening
- Significant hepatobiliary disease and/or any of the following results at Screening:; ALT ≥ 3.0 × ULN; AST ≥ 3.0 × ULN; TBL > 1.5 × ULN (except for cases of known Gilbert's Syndrome)
Where in South Korea
Also in 15 other countries, 211 sites
- AnyangHospital not named in the registryTaking people
- Bucheon-si, South KoreaHospital not named in the registryNot yet recruiting
- DaeguHospital not named in the registryTaking people
- SeoulHospital not named in the registryNot yet recruiting
- YangsanHospital not named in the registryTaking people
About the trial
What the trial wants to find out
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
The 3 groups in the trial
- AZD6234 Dose 1Treatment being tested
Treatment: Lenbelintide
- AZD6234 Dose 2Treatment being tested
Treatment: Lenbelintide
- PlaceboPlacebo, for comparison
Matching placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity Without Type 2 Diabetes Mellitus (SELENE 1)
- Plain-language title
- AZD6234 for adults with obesity or overweight and no type 2 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 30 October 2026